Claim OwnershipPsychopharmacology and Psychiatry Updates
Subscribed: 1,355Played: 133,399
Subscribe
Description
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
413 Episodes
Reverse
In this episode, we challenge conventional prescribing by exploring why lithium should be the first-line treatment for acute classic mania, despite widespread use of antipsychotics. Dr. David Osser presents evidence-based arguments for lithium's unique neuroprotective benefits and long-term efficacy. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: An Update on Bipolar Mania Algorithm Lithium for Bipolar Mania Without Mixed Features
In this episode, we explore a head-to-head comparison of trazodone, doxepin, and melatonin for treating insomnia when benzodiazepines are off the table. Which non-benzodiazepine sleep aid offers the best balance of effectiveness and tolerability in real-world psychiatric patients? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Melatonin, Trazodone, or Doxepin for Sleep Disorders
In this episode, we explore the critical decision of when to add lithium or valproate to second-generation antipsychotics in mixed manic episodes. Should you rush to combination therapy under managed care pressure, or does patience with strategic benzodiazepine bridging lead to better outcomes? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: An Update on Bipolar Mania Algorithm Choosing Between Valproate or Lithium Augmentation for Bipolar Mania With Mixed Features
In this episode, we explore a provocative argument for reconsidering disulfiram as a first-line treatment for alcohol use disorder. Could this decades-old medication, often dismissed as outdated and dangerous, actually be more effective than newer alternatives when used in appropriately selected patients? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Alcohol Use Disorder: Should Disulfiram Be First-Line?
In this episode, we explore the complex pharmacological management of mixed mania, a challenging bipolar presentation affecting up to 40% of manic episodes. Why do traditional mood stabilizers like lithium fall short, and which second-generation antipsychotics emerge as first-line treatments for this dual-symptom condition? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Lithium: How to Manage Dosage and Side Effects Managing Renal Side Effects of Lithium Therapy
In this episode, we explore psychedelic-assisted therapy in clinical practice, examining how these treatments differ fundamentally from traditional pharmacotherapy. Can psychiatrists reconcile mystical experiences with evidence-based medicine while navigating the complex therapeutic paradigm of preparation, 8-hour sessions, and integration work? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry Psychedelic-Assisted Therapy in Clinical Practice
In this episode, we explore groundbreaking research revealing that lower doses of lurasidone (40-60mg) may be more effective for bipolar depression than higher doses. Could we be over-medicating our patients when the sweet spot for both efficacy and tolerability lies in this unexpected lower range? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Lurasidone for Bipolar Depression: What Is the Optimal Dose?
In this episode, we explore a compelling comparison between olanzapine and risperidone for managing behavioral symptoms in dementia patients. Are the delusions we see in Alzheimer's disease actually true delusions, or something entirely different that requires a new treatment approach? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 73 Alzheimer's Disease: Olanzapine vs. Risperidone for BPSD
In this episode, we explore the complex drug-drug interactions between psychedelics and psychiatric medications. Do SSRIs really blunt psychedelic effects, or is this just clinical folklore? We'll examine surprising new research and discuss potentially dangerous combinations every psychiatrist should know. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry Examining the Combined Use of Psychedelics and Psychiatric Drugs
In this episode, we challenge the conventional wisdom of "what gets them well keeps them well" by exploring groundbreaking Finnish research on bipolar disorder medication dosing. Does maintaining patients on high doses actually improve long-term outcomes, or could standard doses be the optimal strategy for relapse prevention? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Bipolar Disorder Maintenance: What's the Optimal Dose Range?
In this episode, we explore how psychedelics like psilocybin disrupt the brain's default mode network, creating windows of neuroplasticity that correlate with mystical experiences and therapeutic breakthroughs in treatment-resistant depression, anxiety, and addiction. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry How Psychedelics Influence Brain Networks
In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Long-Acting Injectables: Superior for Reducing Mortality in Schizophrenia?
In this episode, we explore the fascinating mechanisms behind psychedelic drugs in psychiatry, examining how substances like psilocybin and LSD work through 5-HT2A receptors to promote neuroplasticity. What if these compounds are hijacking an ancient stress response system designed to help us rapidly adapt to survive? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry The Mechanisms and Effects of Psychedelics
In this episode, we explore groundbreaking research comparing weight gain across eight common antidepressants. Using data from 183,000 patients, this study finally provides concrete numbers to answer the question patients ask most: How much weight will I gain on this medication? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?
In this episode, we explore lisdexamfetamine as the first FDA-approved medication for binge eating disorder. Can one medication effectively treat both ADHD and binge eating simultaneously? We examine the evidence, duration of treatment, and strategies for addressing patient ambivalence in eating disorder pharmacotherapy. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Binge Eating Disorder Pharmacotherapy: Lisdexamfetamine
In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?
In this episode, we explore pharmacotherapy for binge eating disorder, examining how antidepressants, anticonvulsants, and emerging treatments target different patient goals. Should your treatment focus on stopping binge episodes or achieving weight loss? We discuss evidence-based approaches to align medication choices with patient priorities for optimal outcomes. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Binge Eating Disorder Pharmacotherapy: Antidepressants and Anticonvulsants
In this episode, we explore the confusing world of lithium therapeutic levels with Dr. Paul Zarkowski. Why do different labs recommend different ranges for the same medication? We examine expert consensus on optimal dosing strategies for both acute treatment and maintenance therapy in bipolar disorder. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 What is the Optimal Therapeutic Range for Lithium in Bipolar Disorder?
In this episode, we explore evidence-based pharmacotherapy for bulimia nervosa, including why higher doses of SSRIs work better than standard dosing, which medications to avoid completely, and how antidepressants can be effective even without depression being present. Why does fluoxetine require 60 mg daily for optimal results? Faculty: Scott Crow M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Bulimia Nervosa: Medications That Work
In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Antipsychotic-Induced Weight Gain: Best Management Strategies
Download from Google Play
Download from App Store
United States
handing out benzos like candy
Hello. My 7 year old adapted daughter had severe agitation episodes. Our paychiatriat impression was PTSD, ODD and ASD. She gave her Risperidone for 3 months which only alleviated her agreasive behaviour, but only for 2 weeks. But she got unilateral painfull Gynecomastia. Then The pschychiatrist changes that to Fluoxetine 10 mg woth breakfast and Aripiprazole 5 mg with launch. Her agitation and anger episodes got very better and her concentration and cognitive funxtion got bette, too. But she stil has difficulty communicating with her peers and episodes and mania. She is obsessive to changing her clithes and is very jealous to other children. We tried to calm the environment but her behaviours makes us as parenta and her sister very concerned. What is the best next aproach? Sam